Could better nutrition help fight Slow-Growing tumors?
NCT ID NCT07302100
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study at Strasbourg University Hospital will check the nutritional status of 100 adults with gastroenteropancreatic neuroendocrine tumors. Researchers want to see if malnutrition is linked to worse outcomes. The goal is to understand whether improving nutrition could help patients with these slow-growing cancers.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could show that tracking and improving nutrition may help patients with slow-growing neuroendocrine tumors live better and longer.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures nutritional status, so it cannot prove that changing diet improves outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Feb 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults aged 18 to 70 years being monitored for a digestive neuroendocrine tumor (gastric, pancreatic, intestinal), diagnosed between January 1, 2000, and November 30, 2024
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18 to 70 years * Patients being monitored for a digestive neuroendocrine tumor (gastric, pancreatic, intestinal), diagnosed between January 1, 2000, and November 30, 2024 Exclusion Criteria: \- Tumor reclassified as non-neuroendocrine by histopathology
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastroenteropancreatic neuroendocrine tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Service d'Endocrinologie, Diabétologie, Nutrition - CHU de Strasbourg - France
RECRUITINGStrasbourg, 67091, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Swiss registry aims to map rare neuroendocrine tumors
- Can a black seed extract boost immunotherapy against a rare cancer?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Massive study to map Real-World GEP-NET care
- Could a liver artery shot make cancer treatment more effective?
- Double PET scan may unlock secrets of gut tumors